Needham & Company Sees 150% Upside in Cytokinetics (CYTK) after Expanded Amgen (AMGN) Deal
Go back to Needham & Company Sees 150% Upside in Cytokinetics (CYTK) after Expanded Amgen (AMGN) Deal| Amgen Inc (NASDAQ: AMGN) | Delayed: 273.01 -0.53 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $273.54 | 52 Week High | $176.85 | |||
| Open | $270.63 | 52 Week Low | $133.64 | |||
| Day High | $274.86 | P/E | 41.12 | |||
| Day Low | $269.65 | EPS | $6.64 | |||
| Volume | 2,467,116 | |||||
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 66.82 +1.25 (1.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.57 | 52 Week High | $13.18 | |||
| Open | $65.89 | 52 Week Low | $6.00 | |||
| Day High | $67.45 | P/E | N/A | |||
| Day Low | $65.68 | EPS | $-1.24 | |||
| Volume | 807,781 | |||||
